Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Three-Part, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

NCT04233918 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT04233918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04233918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Three-Part, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia
Lead sponsor
Regeneron Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
June 29, 2020
Completion date
May 30, 2023
Enrollment
20 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

homozygous familial hypercholesterolemia